wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38077440-58078D8D-5A66-4B9B-B2C7-420038D9A06B
Q38077440-58078D8D-5A66-4B9B-B2C7-420038D9A06B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38077440-58078D8D-5A66-4B9B-B2C7-420038D9A06B
Safety and feasibility of targeted agent combinations in solid tumours.
P2860
Q38077440-58078D8D-5A66-4B9B-B2C7-420038D9A06B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38077440-58078D8D-5A66-4B9B-B2C7-420038D9A06B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d2949263c09de75c60c8617c4b26c65dae1ae31f
P2860
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.